Citizens JMP lowered the firm’s price target on Astria Therapeutics (ATXS) to $25 from $26 and keeps an Outperform rating on the shares. Data for navenibart expected mid-year could bolster confidence in Astria’s extended dosing intervals with the first clinical data for STAR-0310 following in Q3, the analyst tells investors in a research note. Astria is executing well on its Phase 3 ALPHA-ORBIT trial of navenibart, and Citizens continues to like navenibart’s positioning within the hereditary angioedema pipeline.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATXS: